ArticleOncotarget2017

A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.

Nannan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.